Additionally, the study established a promising safety profile, with common grade 3 or higher adverse events including neutropenia and fatigue.27 Recent research suggests that RC48 exhibits favorable efficacy in patients with both HER2-positive and HER2-low-expression BC, without any new safety concerns.28 The gene discussed is ERBB2; the disease is breast cancer.